Lisätietoa aiheesta

PROMs assessing cancer specific quality of life

Additional information
16.4.2025
EAU guideline panel
Table 1. PROMs assessing cancer specific quality of life «Ratti MM, Gandaglia G, Alleva E, ym. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. Eur Urol Oncol 2022;5(2):153-163 »1
QuestionnaireDomains/items
European Organisation for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) «Groenvold M, Klee MC, Sprangers MA, ym. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epi»2Five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); global health status/QoL scale; and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease.
European Organisation for Research and Treatment of Cancer QLQ-PR 25 (EORTC QLQ-PR 25) «van Andel G, Bottomley A, Fosså SD, ym. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Can»3Urinary, bowel and treatment-related symptoms, as well as sexual activity and sexual function.
Functional Assessment of Cancer Therapy-General (FACT-G) «Cella DF, Tulsky DS, Gray G, ym. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570-9 »4Physical well-being, social/family well-being, emotional well-being, and functional well-being.
Functional Assessment of Cancer Therapy-Prostate (FACT-P) «Esper P, Mo F, Chodak G, ym. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50(6):920-8 »512 cancer site specific items to assess for prostate-related symptoms. Can be combined with FACT-G or reported separately.
Expanded prostate cancer index composite (EPIC) «Wei JT, Dunn RL, Litwin MS, ym. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate ca»6Urinary, bowel, sexual, and hormonal symptoms.
Expanded prostate cancer index composite short form 26 (EPIC 26) «Szymanski KM, Wei JT, Dunn RL, ym. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among pr»7Urinary, sexual, bowel, and hormonal domains.
UCLA Prostate Cancer Index (UCLA PCI) «Litwin MS, Hays RD, Fink A, ym. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36(7):1002-12 »8Urinary, bowel, and sexual domains.
Prostate Cancer Quality of Life Instrument (PCQoL) «Giesler RB, Miles BJ, Cowen ME, ym. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res 2000;9(6):64»9Urinary, sexual, and bowel domains, supplemented by a scale assessing anxiety.
Prostate Cancer Outcome Study Instrument «Giesler RB, Miles BJ, Cowen ME, ym. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res 2000;9(6):64»9Urinary, bowel, and sexual domains.

References

  1. Ratti MM, Gandaglia G, Alleva E, ym. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. Eur Urol Oncol 2022;5(2):153-163 «PMID: 34785188»PubMed
  2. Groenvold M, Klee MC, Sprangers MA, ym. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997;50(4):441-50 «PMID: 9179103»PubMed
  3. van Andel G, Bottomley A, Fosså SD, ym. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008;44(16):2418-24 «PMID: 18774706»PubMed
  4. Cella DF, Tulsky DS, Gray G, ym. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570-9 «PMID: 8445433»PubMed
  5. Esper P, Mo F, Chodak G, ym. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50(6):920-8 «PMID: 9426724»PubMed
  6. Wei JT, Dunn RL, Litwin MS, ym. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56(6):899-905 «PMID: 11113727»PubMed
  7. Szymanski KM, Wei JT, Dunn RL, ym. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010;76(5):1245-50 «PMID: 20350762»PubMed
  8. Litwin MS, Hays RD, Fink A, ym. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36(7):1002-12 «PMID: 9674618»PubMed
  9. Giesler RB, Miles BJ, Cowen ME, ym. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res 2000;9(6):645-65 «PMID: 11236855»PubMed